Counting my change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
pcrutch...Great DD articles.Thanks
POSC: Some facts on Positron
There is a lot of information and talking going on at the moment, so it is important to put things in perspective and try to remove a certain amount of emotion. We can do this by setting the facts out there and building from there.
1) POSC recently presented at MedAxiom in Washington DC. The MedAxiom Spring Conference targets 5400 physicians covering 45 states with approximately 65% of current attendees being CEO’s and other high-level administrators, and the other 35% being cardiologists.
2) Recent changes in reimbursements for PET and SPECT imaging have created an additional market for the Attrius on top of the need for better cardiovascular imaging.
"This fee schedule states that Myocardial PET perfusion imaging was increased 20% to $1,432.87 per study. The Schedule also states that Cardiovascular SPECT reimbursement for outpatient cardiology practices billing under CPT codes has been reduced by 36%."
3- SPECT imaging is in trouble because world shortage of the Molybdenum-99. Cardiac PET uses Rubidium-82 and possibly flurpiridaz, or F18. This opens up expanded use of PET scanners and studies have shown higher resolution using these agents over SPECT agents.
4- PET scanners made by POSC will compete due to price-point. PET-CT machines typically cost upwards of $2 million, while the Attrius will be nearly half that cost. They are also aiming at getting these into private practices, not just imaging centers and large hospitals.
5- They recently won the Frost & Sullivan award, 2010 North American New Product Innovation Award in Cardiac Molecular Imaging Systems. This is significant since Frost & Sullivan is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies.
They chose Positron's(POSC) Attrius based on 5 criteria: (1)Innovative Element of the Product
"With the introduction of Positron Corporation’s Attrius cardiac PET scanner, the issues surrounding sensitivity of PET imaging like size of detector, distance from patient, detector encoding scheme, parallelism of the electronics, and packing fraction are greatly reduced. The Positron Attrius scanner’s design is optimized for cardiac imaging unlike their competition with PET/CT. The Positron Attrius was created with a lower price tag, smaller footprint, reduced radiation exposure to the patient, improved workflow, provisions for rapid quantitation and improved serviceability."
(2)Leverage of Leading Edge Technologies
"Positron’s quantitative cardiac specific therapy monitoring software was initially developed in partnership with an industry leading cardiologist with the primary goal of permitting easy interpretation of even the most complex clinical cases. The Attrius product is equipped with a robust, cardiac specific, imaging software which can execute on multiple processors to provide concurrent acquisition, reconstruction, image processing, and display, as well as other key functions including data archiving, without interference. Positron’s leading edge hardware and software truly sets them apart from their competition."
(3)Value Added Features/Benefits
"Positron Corporation’s Attrius cardiac PET scanner is one of the highest 2D sensitivity systems on the market today. It features more uniformity achieved in its slice sensitivity, consistency in the quantitation from slice-to-slice, and the ability to more accurately define the locale of a lesion or perfusion defect. Furthermore, Positron’s unique, shorter septa detector design enables it to achieve dynamic performance efficiency. As a result, Attrius boasts cooler operating conditions for improved electronic reliability versus the competition. Additional features include heart disease specific software including the ability to monitor therapy, coronary artery overlay display, open architecture for new protocol development and customization and motion correction software. The Attrius, when added to a medical practice or hospital will add benefit to all parties along the treatment paradigm."
(4)Increased Customer Value
"Positron’s Attrius scanner is designed to provide a significantly lower cost of ownership as compared to PET/CT modalities. Positron’s rapid segmented attenuation correction scanning allows for scan times competitive to that of PET/CT. Moreover, the Attrius product’s gantry design minimizes the floor space required for installation. This in turn enables PET to be installed in clinics wherever floor space is a premium. Overall, Positron is committed to leading this new quantitative dimension in PET imaging by designing the Attrius product line with fewer boards, easier access to the detector modules, and boards due to the flexible rear nosecone shield design, fewer power supplies, fewer lighter gauge cables, and automated tuning features imbibed within it. The Attrius was designed with a small footprint, allowing the system to fit into a 15’ x 20’ space. The table limit was increased to 450 lbs, permitting larger patients to be imaged. The table is also capable of loading patients from the front or back, improving the position options for imaging."
(5) Customer Acquisition/Penetration Potential
" The cardiac PET market is expanding evidenced by large and mid-sized pharmaceutical companies developing single-dose F-18-based cardiac perfusion agent in response to renewed interest. PET is becoming more in demand than PET/CT with a lower cost of entry. New scanners, such as Positron’s, are updated to today’s standards. With the newly-minted FDA approval, Positron can now ramp up production and sales to cardiology offices and hospitals. The device seems well timed given the current urgency to curb costs, reduce patient radiation exposure and demonstrate effectiveness as the U.S. considers health care reform options. The product line is manufactured in Shenyang, China, through their joint venture with Neusoft Medical Systems. Their manufacturing facility has a large capacity which enables Positron to meet even the highest demand for the product.
Positron’s Attrius is the only dedicated PET available today for the thousands of cardiologists and hospitals looking for a solution to today’s imaging challenges."
Source
6- The CEO confirmed to shareholders in the last month that,
" Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
Tomorrow should be an interesting day. I am still holding for the news and will be updating tomorrow based on relevant news released. GLTA.
Posted by Patrick at 6:51 PM 4 comments
Labels: POSC
Friday, April 23, 2010
POSC: More about the Attrius and it's market
I decided to make a new post for this since the other one got rather long. As the article below describe, the Attrius is serving a specific, but high-demand market, namely cardiac PET.
Recently, there is a stack of evidence pointing towards the ascension of this company and the Attrius. In the past 4 months, they have sold 2 of the machines, won the Frost & Sullivan award, increased demand by non-radiologists. These sales and market direction seem to be unnoticed by most, but not any longer.
In January, they announced the sale and installation an Attrius scanner to a prominent cardiology practice,
" Positron Corp., a molecular imaging solutions company focused on Nuclear Cardiology, announced the sale and installation of its PET scanner to Manhattan based, Gramercy Cardiac Diagnostic Services, owned by New York City cardiologist, Dr. Peter Rentrop."
Joseph Oliverio, Chief Technology Officer of Positron said, "Dr. Rentrop is a leader in the nuclear cardiology field and has been performing SPECT imaging in the greater New York City area for decades and we are proud that he selected Positron for his Cardiac PET imaging device." Oliverio further said, "Dr. Rentrop's addition of PET imaging to complement his SPECT business further validates cardiologist's move towards PET and the acceptance of the technology as the future of nuclear cardiology. Positron has the ideal solution for thousands of cardiology groups looking to improve their diagnostic accuracy at an affordable price."
Dr. Peter Rentrop added, "I am delighted with the opportunities that PET gives Gramercy Cardiac's partner physicians to extend and improve the services they provide to the patient communities of New York. The improved diagnostic accuracy of PET will prove invaluable in improving patient outcomes and I am glad to be partnering with Positron in this program." _________________________________________________
Additionally, in March, they announced the sale of its Attrius PET scanner to Ochsner Health System of Louisiana
"Robert Bober, M.D., F.A.C.C, Director of Nuclear Cardiology at Ochsner states, “We are eager to offer Louisiana residents the best technology for coronary disease detection.” Dr. Bober went on to state, “We selected Positron as our preferred vendor due to their dedication to high quality cardiology imaging and their vast amount of experience in this field.”
Joseph Oliverio, Chief Technology Officer of Positron states, “The Attrius sale to Ochsner demonstrates our expanding market beyond private cardiology practices. We are grateful to have such a prestigious hospital network join our user group.” Oliverio further stated, “Positron has the ideal solution for thousands of cardiology groups and hospitals looking to improve their diagnostic accuracy at an affordable price. As a Company we have always been at the forefront of cardiac PET and see the market for our products and industry continue to expand at a rapid rate. As evidence we are experiencing an unprecedented demand for our new device.”
_________________________________________________
Growth rate of the market
What you notice here is an increased use by non-radiologist, namely cardiologists, looking to add value through the price point of the Attrius and it's accuracy.
Recently, in a study " in the March issue of the Journal of the American College of Radiology (JACR Volume 7, Issue 3, March 2010, Pages 187-191).
The data for the study was collected utilizing the Medicare Part B Physician/Supplier Procedure Summary Master Files for 2002 through 2007.
The study states "Although a large percentage of PET scans in private offices are done by radiologists (45.4 percent in 2007), the growth rate among nonradiologists was far higher (737 percent) than radiologists (259 percent) between 2002 and 2007 and private-office PET market share for nonradiologists rose from 13 percent in 2002 to 24 percent in 2007”, according to Rajan Agarwal, MD and colleagues at the department of radiology, University of Pennsylvania Health System in Philadelphia. "
Additionally, the Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule was released stating the following:
"The Medicare Physician Fee Schedule outlines the payment rates for medical services paid to private physicians in the outpatient office setting. This fee schedule states that Myocardial PET perfusion imaging was increased 20% to $1,432.87 per study. The Schedule also states that Cardiovascular SPECT reimbursement for outpatient cardiology practices billing under CPT codes has been reduced by 36%."
So physicians are going to have to switch to PET scans in order to cost-effectively run their practice. Also, SPECT are in trouble because of "the world shortage of the molybdenum-99 isotope for the near future." Positron has already been working around this.
"Positron also has been in contact with Bracco Diagnostics of Princeton, NJ, which markets the PET radiopharmaceutical CardioGen-82 (rubidium Rb 82 generator), the only generator-based PET cardiac perfusion agent approved by the FDA and reimbursed for coronary artery disease evaluation.
"We have been in close contact with them and they have reassured us that there is a significant demand for [a PET-only cardiac system]," Oliverio said. "
______________________________________________
Added Efficacy and Efficiency
The Attrius adds value to the practice in several ways.
1- Lower radiation levels.
2- Improved accuracy
3- A radiologist is not needed.
4- Reduce unnecessary, potentially invasive procedures
"The device offers a coronary disease quantitative software package written by cardiac PET pioneer Dr. K. Lance Gould from the University of Texas Medical School at Houston. In addition, Positron plans to offer ejection fraction analysis and CT angiography fusion with PET data through third-party software."
" Many in the industry are looking for new technologies to improve their diagnostic accuracy, improve patient outcomes, reduce patient radiation exposure all while adding to their bottom line. The elusive solution to this dire situation may lie in an already well established, underutilized imaging modality: PET.
While PET is a more costly procedure than the SPECT imaging, the use of PET in cardiac nuclear medicine has been shown to reduce long-term costs and resolve clinically complicated cases. The accuracy of PET helps reduce the need for unnecessary angiograms. It can also reduce bypass surgeries by more accurately risk stratifying patients that may require the invasive procedure from those that might benefit from alternative therapies. This modality has also been shown to quantitatively monitor therapy, which helps provide personalized medicine plan for each patient. PET, specifically without a CT, has shown to have the lowest radiation exposure for the assessment of coronary disease.
"Positron's Attrius is the only dedicated PET available today for the thousands of cardiologists and hospitals looking for a solution to today's imaging challenges," concludes Prasanna Kannan. "Implementing a PET program will allow cardiologists and hospitals to improve their diagnostic accuracy, reduce unnecessary downstream procedures, reduce patient radiation exposure, and practice more efficiency while improving their bottom line."
"With cardiac PET, it is known that it will have a clinical benefit if it is put into practice," Oliverio said. "At the same time, the ability to monitor therapy and take advantage of the trends of medicine going toward proactive, nonsurgical methods, and the ability to track coronary disease progression, reversal, or cessation of disease, is priceless, in my opinion."
from chasing alpha
Thanks, Welcome aboard!!
Hi Kei, I agree it does trade crazy. I will be holding at least thru this week on its forward moving event.This is strictly a lotto play and trade.
The panic were people who wanted instant gratification.The over-all news was great.
Updated: POSC to present at Nasdaq Marketsite
Written by Staff and Wire Reports
Monday, 26 April 2010 06:45
A senior POSC official has confirmed to BioMedReports that a "very important and positive development regarding a partnership whose details can not yet be discussed" will be presented at the announced press conference. "Obviously, the company has gone through great expense and effort to organize this important event, and we would not be undertaking such tasks if the announcements we have have to make weren't important to our company and it's shareholders," said the official.
The following was released by the company via press release this morning:
Positron Corporation (OTCBB:POSC), a molecular imaging solutions company focused on Nuclear Cardiology, today announced that its CEO Patrick Rooney and senior executives will present at the NASDAQ MarketSite in Times Square, New York City, NY.
Positron Corp
0.16 -0.09 (-34.80%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
They will discuss new initiatives and recent highlights including their Frost & Sullivan 2010 North American New Product Innovation Award for their Attrius PET Scanner.
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY
Hi aoccoa...I have found nothing on any PDMI's FDA approval. I own a small position in this stock.I will post any information I may find.
And do we remember this?
Health Sciences Group Engages Into Conversation With Medical Marijuana, Inc. About Consulting / Co-R&D Venture
Release Date: 10/29
Health Sciences Group, Inc. is proud to announce that its CEO Thomas Gaffney has engaged in preliminary conversations with Bruce Perlowin, Founder, Chairman, & CEO of Medical Marijuana, Inc. (MJNA), about the possibilities of the companies merging co- research and development and consulting services. "These conversations were preliminary in nature. I look forward to more discussions with Mr. Perlowin about the services Medical Marijuana, Inc. provides and how we can work together to grow our companies and increase shareholder value on both sides." I will be doing more DD. All of this is interesting including the spike on volume on Friday.
Interesting Question...Why is the Medical Marijuana ,Inc MJNA Logo link on HESG's site? Interesting http://www.igohealthy.org/
Have a great weekend PIE!
Typical Friday sell off.No big deal BIEL is still looking good
Alert on POSC...POSC's big news conference will be officially announced on Monday per BioMeds
Following up on the rumors we have been chasing for two weeks, it appears that staffers at Positron Corporation (OTCBB:POSC) have been busy making arrangements for a soon to be announced press conference.
This news according to multiple sources who also told BioMedReports on Thursday that an official announcement about "a big development for the company" may be issued as early as Monday.
Yesterday, prices took a hit after a blogger made false and defamatory accusations against not only BioMedReports, but the company as well. This is the second time that the blogger has attacked BioMedReports's and owners of this website intend to take swift and complete legal action against the owner/author of that web site. Thus far, after multiple requests, the author of the website has refused to provide us with his legal contact information so that our legal department can commence those actions.
The fact remains that POSC is an established company that has been in business for over a quarter of a century and that a positive announcement- apparently worthy of a press conference- will be made public in the coming days. Speculation continues that a multi-billion dollar company trading on the NYSE at over $50 per share has taken an interest in the company.
Furthermore, sources at the company tell BioMedReports that pending orders for their FDA approved, Frost and Sullivan award winning imaging system run at least "over one hundred deep."
As we told subscribers two days ago, we fully expect the stock price to see substantial gains (beyond the initial 43% gains seen immediately after our trade alert) as it now appears that the company had positioned itself to be the clear leader in the five billion dollar molecular imaging market. Positron's PET (Positron Emission Tomography) scanner, known as the “Attrius”, has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the entire industry (see related story).
In a letter to shareholders last month, the chairman of the board for the company informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
It is clear that a positive development worthy of a full press conference (rumored arrangements place it at the Nasdaq MarketSite in New York City) may be officially announced as early as Monday.
If true, naked shorters who took negative positions in the stock will not only have to cover, they will help push the stock price much higher by doing so.
Developing...
I agree with you 100% PIE. This is a great additional step in marketing. I am checking with management when they are going to upgrade their online ordering to accept credit cards.
Alert from Bio Meds...Sources tell BiomedsReports that POSC has scheduled a news conference which will be held at the Nasdaq Market Site according to those sources.POSC will not deny that a news conference will be announced by Monday!
HEB up 6.76%
CYTX building steam every day
Added POSC shares....A good lotto play.Possible buy out or partner
Chairman of the Positron Corporation (OTCBB: POSC) Confirms Talks; Sources Say Partnership or Buy-Out News May Follow Next Week
marketwire
Press Release Source: BioMedReports On Thursday April 22, 2010, 7:00 am EDT
LOS ANGELES, CA--(Marketwire - 04/22/10) - As rumors of a lucrative buy-out or partnership continue to swirl, Patrick G. Rooney, the Chairman of the Board of Positron Corporation (OTC.BB:POSC - News) -- a molecular imaging company focused on Nuclear Cardiology -- has confirmed in an interview with BioMedReports that his company "is currently in discussions with a potential partner in our industry."
While Rooney did not offer any assurances or details about when an agreement might be reached. Over the past two weeks, however, multiple sources have told the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors that details about "a big announcement involving Positron and a much larger publicly traded NYSE company" could come as early as next Monday.
BioMedReports told its subscribers on Wednesday that stock prices for the twenty-seven-year-old company could see substantial gains now that the company had positioned itself to be the leader in nuclear cardiology imaging. Positron's PET scanner, known as the "Attrius," has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the industry.
In a letter to shareholders last month, Rooney informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
According to today's exclusive report, Rooney feels confident that his company will thrive financially given that "the cardiac business is five times greater than the oncology business."
"Everyone has a heart problem; not everyone has cancer," said Rooney. "Once you have a heart issue, they'll put you on some kind of imaging device to test your heart. It's just where medicine is going. Everyone over 45 or so is starting to get imaged at the first sign of any heart issues."
Positron recently won the 2010 Frost and Sullivan "North American Molecular Imaging Systems New Product Innovation Award."
The complete special report and video about the company is available at BioMedReports.Com.
Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
Contact:
Media Contact:
Mary Davila, Assistant Editor, BioMedReports.Com
e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556
Trading Update for POZEN
Posted on 04/21/2010 by Leo Goldman (leo.goldman@marketintellisearch.com)
NEW YORK (Market Intellisearch) -- POZN options saw interesting call activity today. A total of 482 put and 2,666 call contracts were traded raising a low Put/Call volume alert. Today's traded Put/Call ratio is 0.18. There were 5.53 calls traded for each put contract.
Put/Call ratio is often used to measure investor sentiment, the ratio serves as a predictor of investor behavior. A high Put/Call ratio suggests that the investor sentiment is bearish and that investors expect the underlying stock to decrease in value. In contrast, a low Put/Call ratio suggests that the investor sentiment is bullish and that the underlying stock is expected to increase in value. Unusual volume provides reliable clues that the stock is expected to make a move.
Shares of POZN closed at $10.30 in the previous trading session and opened today at $10.30. POZEN settled the day up $0.49 to $10.79 in the trading session. The day's trading range is between $10.20 and $10.97 respectively. On the volume side, 855,742 shares were traded which is greater than the average volume of 254,613 shares. POZN is trading above the 50 day moving average and higher than the 200 day moving average. The stock's 52 week low is $5.16 and 52 week high is $11.66.
INTERESTING READ..MCCI... MUST READ.... here the scoop OR DD for all looking to invest in MCCI..
the president of marketing concept intl.MCCI} has recently passed away .so am led to believe that the silent of the company aka lack of PR was due to the fact that the C.E.O. Mr mann was ill leading up to his death recently.
2}There has been changes in board members as stated on pinksheets.
we longs of mcci for month has been speculating that there was a merger in works. after many DD and many clues along the way
WE CAN SAY THAT WE FINALLY GOT IN CONTACT WITH THE C.E.O OF SEAKINETIC AND THE C.E.O HAS CONFIRMED VIA" PHONE CALL THAT THE MERGER WAS A SUCCESS ...YES THE MERGER DID HAPPENED HUGE NEWS FOR MCCI... AND FOR MANY REASONS AS STATED BELOW.
NOTE:SKTS is in the process of becoming fully PK reporting withing the next few weeks and a huge PR will follow stated by Mr. Jagtar (Jack) Dhaliwal – Executive Vice President, Chief Technology Officer, Director of seakinetics.
3}RECENT PR
The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.
4}AS the PR stated the benifts of the merger are: mcci share price should rise dramatically, and with the company history of not having a R/S since 2004 we should have a share buy back which we all know rises a share price.
5}owners of {skts} and {mcci} history:
seakinetics trades in germay at $1.75
marketing concepts intcc. trades at .0002.
MCCI ceo: mr kenneth mann aka former ceo, and
SKTS ceo:James C Shelley, President, CEO & Director
were both on the board of directors for Americhip company.seems mr mann was the president of americhip during 2008 and shelly seems to be director of americhip international as well so they both worked together before and also were possible friends as well.
6}MCCI OFFICIAL UPDATES FROM TDAMERITRADE ASSOCIATES! unchanged ss: **The total shares outstanding for Marketing Concepts as of 1-25-2010 are 1,999,980,416 shares outstanding with 1,905,867,327 shares free trading and 94,113,089 restricted with 2,000,000,000 shares authorized.
We are confirming with the company if there is a change of officers.
Thank you,
Jason M. Bogutski-President
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Tel 972 612 4120
Fax 972 612 4122
Email - signaturestocktransfer@msn.com
7}. Unlike traditional venture capital firms, MCCI will generate
revenue from net sales even if the client corporation is not
yet profitable. This means a greater return in a shorter period
of time with less risk.
B}. As a significant portion of the revenue earned will be distributed
directly to our shareholders; there will be much less risk.
C}. The shareholder income distribution will insure that there is an
inherent value to MCCI shares, and should serve to maintain a
stronger and more consistent share value.
D}. With the option to acquire 25% of the client corporation after
three years of sales activity, we can promise our shareholders
that the value of the acquisition will far exceed the investment
cost. The structure of the basic agreements between Marketing
Concepts and its clients will substantially reduce risks usually
Associated with this type of investment.source..from the YB
No problem Weathervane. I truly believe we have a good one here and it won't be under radar for long.
EVRM...but my 2nd love is EVRN
CCC...Great call on CYTX
Glad to have you here,Rocketstocks!!
SPPI NEWS!
Wed, Apr 21, 2010, 8:08AM ET - U.S. Markets open in 1hr 22mins.
Spectrum Pharmaceuticals Announces Belinostat Data Presentation at 101st Annual Meeting of the American Association for Cancer Research
* Data Suggest HDAC Inhibitors, Such as Belinostat, May Be Efficacious in the Treatment of Small Cell Lung Cancer
* Results Indicate Synergy With Conventional Chemotherapy Agents
businesswire
Press Release Source: Spectrum Pharmaceuticals, Inc. On Wednesday April 21, 2010, 8:00 am
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI - News), a commercial-stage biotechnology company with a primary focus in oncology, today announced results of a pre-clinical study conducted by the National Cancer Institute of belinostat in the treatment of small-cell lung cancer that was presented in a poster session on Wednesday, April 21, 2010 at the 101st Annual Meeting of the American Association for Cancer Research (AACR), being held at the Walter E. Washington Convention Center in Washington, DC.
“Based on the data presented today at AACR, we believe belinostat may be an effective treatment option for small-cell lung cancer,” said Rajesh C. Shrotriya, MD, Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “While we continue to enroll patients into the 100-evaluable patient registrational trial for belinostat in peripheral T-cell lymphoma (PTCL), being conducted under a Special Protocol Assessment by the FDA, we are exploring potential clinical trial design options for the treatment of lung cancer.”
Abstract #5372 – Synergy of Histone Deacetylase Inhibitors, Belinostat and Depsipeptide, With DNA Damaging Agents, Etoposide and Cisplatin, In Small Cell Lung Cancer Cell Lines
Small Cell Lung Cancer (SCLC) is the most aggressive type of lung carcinoma. SCLC has a high response rate to chemotherapy, but rapid onset of drug resistance. Chemotherapeutic treatment using combinations of drugs that target different signaling pathways have demonstrated improvement in overall survival of patients with SCLC. HDAC inhibitors play a role in regulating cell cycle progression and have been suggested as potential therapeutic agents for SCLC. HDAC inhibition is believed to relax DNA, thereby allowing increased access of transcription factors to certain promoters. Likewise, these agents could increase accessibility of DNA to cytotoxic agents.
Two distinct HDAC inhibitors, belinostat and depsipeptide, were examined to determine whether they have an effect on SCLC lines and whether they could be combined with conventional chemotherapy agents etoposide and cisplatin for SCLC.
Simultaneous and schedule-depended treatment protocols of SCLC cells with single drugs and drug combinations were used. Computational analysis of cell survival using combination index (CI) showed that HDAC inhibitors synergized with DNA damaging agents when administered simultaneously, but this effect was only additive if cells were pre-treated with HDAC inhibitors for 24 hours prior to DNA damaging agents. In addition, using DNA damaging agents 24 hours prior to HDAC inhibitors was clearly antagonistic with CI>1 for all drugs and cell lines tested.
Because of a potential use of belinostat and depsipeptide for therapy of SCLC in combination with conventional chemotherapies, the mechanisms of synergy and protection between these agents were examined. PolyADP-ribose polymerase (PARP) degradation was complete when drugs were used simultaneously, but was decreased if HDAC inhibitors were used prior to cisplatin or etoposide. The degradation of PARP enzyme prevents repair of DNA strand breaks caused by chemotherapeutic agents and thereby facilitates the programmed cell death, or apoptosis, of cancer cells. Therefore, a greater degree of PARP degradation is indicative of a greater capacity of a given anti-cancer agent or a combination of agents to induce apoptosis.
It was concluded that HDAC inhibitors synergize with DNA damaging agents only if administered simultaneously. Treatment of cells with HDAC inhibitors and DNA damaging agents induces PARP degradation. Combination of HDAC inhibitors with etoposide does not affect single stranded DNA damage. Simultaneous treatment with DNA damaging agents increases double strand DNA damage. The design of clinical trials for combination of HDAC inhibitors and chemotherapeutic agents should take into account the timing that induces maximum effect.
About Belinostat
Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effect is thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis (programmed cell death), inhibition of angiogenesis, induction of differentiation, and the resensitization of cells that have overcome drug resistance to anticancer agents such as platinums, taxanes and topoisomerase II inhibitors. Belinostat is the only HDAC inhibitor in clinical development with multiple potential routes of administration, including intravenous administration, continuous intravenous infusion and oral administration.
Belinostat is currently in a registrational trial, under a Special Protocol Assessment (SPA), as a monotherapy for relapsed or refractory Peripheral T-Cell Lymphoma (PTCL), an indication for which it has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration. The Company currently plans to file a New Drug Application (NDA) in 2011. Belinostat is also under investigation in a randomized Phase 2 trial, as a combination therapy with carboplatin and paclitaxel, for cancer of unknown primary (CUP). Additionally, the National Cancer Institute is currently conducting several clinical trials of Belinostat in a variety of hematological and solid tumors, both as monotherapy as well as combination therapy.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in hematology and oncology. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to building an efficient in-house clinical research organization with regulatory and data management capabilities, the Company has established a commercial infrastructure for its drug portfolio. The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs in late stage development, apaziquone and belinostat, along with a diverse pipeline. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.
Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, the safety and efficacy of belinostat, that belinostat may be efficacious in the treatment of small cell lung cancer and have synergy with conventional chemotherapy agents, potential clinical trial design options for belinostat for the treatment of lung cancer, that belinostat has multiple potential routes of administration, including intravenous administration, continuous intravenous infusion and oral administration, that the Company currently plans to file a New Drug Application (NDA) in 2011 and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum, TURNING INSIGHTS INTO HOPE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
© 2010 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
Contact:
Spectrum Pharmaceuticals, Inc.
Paul Arndt
Senior Manager, Investor Relations
949-788-6700x216
POZEN NEWS!
POZEN Announces April 29, 2010 Webcast of First Quarter 2010 Results
businesswire
Press Release Source: POZEN Inc. On Wednesday April 21, 2010, 7:30 am
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN - News), announced today that it plans to release first quarter 2010 results on April 29, 2010, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. Eastern time with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2010 earnings release will be accessible in the News section of POZEN’s website.
About POZEN
POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers. The Company’s common stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.
Contact:
POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030
POZEN NEWS!
POZEN Announces April 29, 2010 Webcast of First Quarter 2010 Results
businesswire
Press Release Source: POZEN Inc. On Wednesday April 21, 2010, 7:30 am
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN - News), announced today that it plans to release first quarter 2010 results on April 29, 2010, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. Eastern time with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2010 earnings release will be accessible in the News section of POZEN’s website.
About POZEN
POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers. The Company’s common stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.
Contact:
POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030
LOL!!!
LACO AND FREE,
In one of my conversations with Robert,he did say they would dilute in a controlled manner,not to hurt shareholder value,but to get them to the next level, which is where we have to go to make money.All start ups have to have some dilution so they can grow. This then will get us to the promise land.
I am with you,Brother! Let's make some money!
BNVI NEWS!
Bionovo Announces Patent Issuance for Bezielle(R) (BZL101) for Metastatic Breast Cancer
prnewswire
Press Release Source: Bionovo, Inc. On Tuesday April 20, 2010, 6:43 pm
EMERYVILLE, Calif., April 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq:BNVI - News) announced today that the US Patent and Trademark Office (USPTO) has issued a patent covering a method of using Bionovo's proprietary drug candidate Bezielle® (BZL101) for the treatment of metastatic breast cancer. The patent issued today is Bionovo's second issued patent, with over 70 other patent applications currently pending.
Bionovo's US Patent No. 7,700,136 covers a method of treating breast cancer using an extract of Scutellaria Barbata. This patent also covers the use of Bionovo's proprietary Bezielle® formulation as a monotherapy for the treatment of breast cancer. The patent is expected to provide coverage through at least November 13, 2026.
Bionovo's first issued patent was US Patent No. 7,482,029, issued on January 27, 2009. The patent covers treatment of hot flashes with MF101, which has been demonstrated in clinical trials to safely provide menopausal women with relief from hot flashes. MF101 is the development name for Bionovo's proprietary drug, Menerba®, an oral formulation for the treatment of hot flashes. The patent is expected to provide coverage through at least August 31, 2026.
"Following two positive Phase 1 trials of Bezielle, this is another critical milestone in Bionovo's efforts to develop Bezielle into a valuable treatment option for an indication that needs new, safe treatment options. Furthermore, intellectual property protection is essential for successfully partnering our drug candidates, and further assuring shareholder value creation," said Isaac Cohen, Bionovo's Chairman and CEO.
Bezielle (BZL101)
Bezielle® is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. Bezielle targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. Bezielle stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain largely unharmed.
There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 200,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are still over 40,000 deaths per year due to the disease in the Unites States alone.
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Alert-BNVI NEWS!
Bionovo Announces Patent Issuance for Bezielle(R) (BZL101) for Metastatic Breast Cancer
prnewswire
Press Release Source: Bionovo, Inc. On Tuesday April 20, 2010, 6:43 pm
EMERYVILLE, Calif., April 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq:BNVI - News) announced today that the US Patent and Trademark Office (USPTO) has issued a patent covering a method of using Bionovo's proprietary drug candidate Bezielle® (BZL101) for the treatment of metastatic breast cancer. The patent issued today is Bionovo's second issued patent, with over 70 other patent applications currently pending.
Bionovo's US Patent No. 7,700,136 covers a method of treating breast cancer using an extract of Scutellaria Barbata. This patent also covers the use of Bionovo's proprietary Bezielle® formulation as a monotherapy for the treatment of breast cancer. The patent is expected to provide coverage through at least November 13, 2026.
Bionovo's first issued patent was US Patent No. 7,482,029, issued on January 27, 2009. The patent covers treatment of hot flashes with MF101, which has been demonstrated in clinical trials to safely provide menopausal women with relief from hot flashes. MF101 is the development name for Bionovo's proprietary drug, Menerba®, an oral formulation for the treatment of hot flashes. The patent is expected to provide coverage through at least August 31, 2026.
"Following two positive Phase 1 trials of Bezielle, this is another critical milestone in Bionovo's efforts to develop Bezielle into a valuable treatment option for an indication that needs new, safe treatment options. Furthermore, intellectual property protection is essential for successfully partnering our drug candidates, and further assuring shareholder value creation," said Isaac Cohen, Bionovo's Chairman and CEO.
Bezielle (BZL101)
Bezielle® is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. Bezielle targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. Bezielle stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain largely unharmed.
There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 200,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are still over 40,000 deaths per year due to the disease in the Unites States alone.
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
LACO, I don't disagree with you,but on the other hand, if Paul and Robert over dilute their stock and hurt the PPS they will be hurting themselves. Remember, their shares are restricted.
Just talked to the CEO of ThermaFreeze : They are stepping up marketing big time. They are working on an new infomercial which will be released in the next month.He mentioned that we will see ThermaFreeze on TV soon.They also have a good chance of getting into the Walgreen's chain via the Duane Reed purchase.He mentioned they were in a consumer show in Las Vegas which was a huge success,there were a massive crowds around their booth.As far as,The sports industry goes,they are ready to unleash the marketing for this too.The equestrian market is huge also and they have a new prototype which is just about ready to go. We will be getting multiple Pr's soon as these thing develop. To confirm there are 107,000,000 shares outstanding.
My opinion from my own DD is this is ready to pop big time.I suggest you e-mail them or Joel Noel to get a free sample,I did and the product is amazing.
Good catch. Your are exactly right,if this gets into the Walgreen's chain we will hit a whole new level. This could be huge!!
3 x .0003 bid
4 x .0004 ask
The preferred shares is absolutely true.
The merger has absolutely happened a while ago. No question this is a fact.
Thanks again. I feel we are coming to something very positive,but we will see.Will post as soon as he calls me back.